ZIOPHARM Oncology

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Company will trade on NASDAQ under the new ticker symbol "TCRT" to be effective tomorrow.

Ziopharm Rebrands As Alaunos Therapeutics

HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), a clinical-stage oncology-focused cell therapy company, today highlighted recent operational and corporate updates. The Company also announced that it has changed its name to Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”).

Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics

The clinical-stage biotech saw a slight bounce-back from its lows of last week.

Why Ziopharm Oncology Shares Rose 10.5% on Wednesday

ZIOPHARM Oncology (ZIOP) has been struggling lately, but the selling pressure may be coming to an end soon.

ZIOPHARM Oncology (ZIOP) Sees Hammer Chart Pattern: Time to Buy?

HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the presentation of preclinical data highlighting the potential of neoantigen-specific TCR-T cells for the treatment of solid tumors at the Society for Immunotherapy of Cancer 2021 Annual Meeting.

Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting

ZIOPHARM Oncology, Inc. (ZIOP) CEO Kevin Boyle on Q3 2021 Results - Earnings Call Transcript

HOUSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced financial results for the third quarter ended September 30, 2021 and provided a business update.

Ziopharm Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update

HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it will report financial results for the third quarter ended September 30, 2021 on Monday, November 8, 2021, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 4:30 p.m. ET to provide a corporate update and review the financial results.

Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021

Future FinTech Group

Katapult Holdings

Are short squeeze penny stocks part of your Q4 strategy? The post Best Penny Stocks To Buy Right Now?

Best Penny Stocks To Buy Right Now? 3 Short Squeeze Stocks To Watch

Ziopharm's (ZIOP) stock price falls after the announcement of several restructuring changes to advance the TCR program.

Ziopharm (ZIOP) Down on Workforce Reduction Announcement

Ziopharm Oncology Inc (NASDAQ: ZIOP) announced a restructuring enabling the Company to advance its TCR program.  The Company will eliminate approximately 60 positions and expects the changes will extend the cash runway into 1H of 2023.

Ziopharm Shares Are Trading Lower After Slashing Workforce By Over 50%

The stock price of ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) fell over 8% during pre-market today. This is why it happened.

ZIOP Stock: Why It Decreased Today

Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway

Recent insider stock purchases were more than a little encouraging.

Here's Why Ziopharm Oncology Stock Is Up 18% This Week

Investors need to pay close attention to ZIOPHARM (ZIOP) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike ZIOPHARM (ZIOP) Stock?

The stock price of ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) increased by over 45% during intraday trading. This is why it happened.

ZIOP Stock: Over 45% Increase Explanation

The company hopes to develop cancer treatments based on individualized gene therapies, and has two promising pipeline candidates.

Why Shares of Ziopharm Oncology Jumped on Wednesday

BOSTON and HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that Kevin S. Boyle, Sr., Chief Executive Officer of Ziopharm, is scheduled to participate in five upcoming virtual investor conferences:

Ziopharm Oncology to Participate in September Investor Conferences

Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles

Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions

ZIOPHARM Oncology's (ZIOP) CEO Heidi Hagen on Q2 2021 Results - Earnings Call Transcript

BOSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, August 9, at 4:30 p.m. EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2021.

Ziopharm Oncology to Report Second Quarter Financial Results on August 9, 2021

BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), a clinical-stage cellular therapy company focused on hematologic and solid tumor cancers, today announced that Company management will participate in two upcoming investor conferences:

Ziopharm Oncology to Participate in Upcoming Conferences

– Highlighted distinctive cellular therapy program, market opportunity and value proposition

Ziopharm Oncology Reinforces Clear and Bold Vision for Delivering Value at Annual Shareholders Meeting

ZIOPHARM Oncology, Inc.'s (ZIOP) Interim CEO Heidi Hagen on Q1 2021 Results - Earnings Call Transcript

– Annual shareholder meeting planned for May 19, 2021

News for ZIOPHARM Oncology Stock (ZIOP)